DRUG STUDY

Name: Casilao, Mike Arone H. Date: June 21, 2023

Course/Yr/Blk: BSN IV-B

MEDICATION Classification/ Action Indications Contraindications Side Effects Adverse Effects Nursing Responsibilities
Generic name: Drug Classification To treat for moderate This drug is  Confusion  Seizures BEFORE:
to severe bacterial contraindicated to  Clostridium Difficile
Piperacillin/Tazobactam Pharmacotherapeutic  Verify the
infections patients with:  Dizziness associated diarrhea
Class: doctor’s order
Brand name:  Acute Generalized
 Hypersensitivity  Headache regarding the
Penicillin Exanthematous
Piptaz to penicillin, medication.
Pustulosis
Clinical: beta-lactams,  Insomnia
Usual dosage/ cephalosporins,  Stephen Johnson
 Observe the ten
frequency: Antibiotic or tazobactam Syndrome
 Lethargy rights of
Drug Action: (cross medication
IV (Adults): 4.5 g q6-8h
sensitivity may  Constipation administration.
or 3.375 g q6h. Piperacillin: Binds to occur)
Maximum: 18 g daily bacterial cell wall
 Nausea  Question for
membrane, causing Use Cautiously to
Usual route history of
cell death. Spectrum patient with: allergies and full
Intravenously  Vomiting
is extended compared medication
 Renal
with other penicillin. history; screen
Drug order: impairment
Tazobactam: Inhibits for interactions.
(dosage
Piperacillin + beta-lactamase, an
reduction or
Tazobactam 4.5 g TIV enzyme that can  Educate and
increased
q6 ANST destroy penicillin. verify patient and
interval
SO’s
Drug Interaction: recommended
understanding
if CCr <40
 Concurrent use Therapeutic Effect: about the
mL/min); medication.
of Sodium
Death of susceptible
aminoglycosides restriction;
(e.g.,  Check the
 gentamicin, bacteria. Critically ill medication three
tobramycin) may patients times.
Pharmacokinetics:
cause mutual (increased risk
inactivation Absorption: of renal failure; DURING:
(must give at use alternative  Administer
least 1 hr apart) Distribution: Widely antibiotic, if Piperacillin
 May increase distributed. Enters possible) Tazobactam 4.5
concentration, CSF well only when g q6 ANST via
toxicity of meninges are side drip for 100
methotrexate. inflamed. Crosses the gtts/min
placenta and enters
 Probenecid may
breast milk in low AFTER:
increase
concentrations.
concentration,  Advise patients to
risk of toxicity. Protein binding: 16- report rash and
 High-dose 30% signs of
piperacillin may superinfection
Metabolism and
increase risk of (black furry
Elimination:
bleeding with overgrowth on
Piperacillin (68%) and
NSAIDs, platelet tongue, vaginal
tazobactam (80%) are
inhibitors, itching or
mostly excreted discharge, loose
thrombolytic
unchanged by the or foul-smelling
agents, and
kidneys. stools) and
warfarin.
Pharmacodynamic: allergy.
 Observe patients
Half-life: Adults: 0.7– for signs and
1.2 hr symptoms of
anaphylaxis
Onset: Rapid
(rash, pruritus,
Peak: End of Infusion laryngeal edema,
wheezing).
Duration: 4-6 hour Discontinue the
drug and notify
health care
professionals
immediately if
these occur.
 Monitor bowel
function.
Diarrhea,
abdominal
cramping, fever,
and bloody stools
should be
reported to health
care professional
promptly as a
sign of
Clostridium
difficile-
associated
diarrhea (CDAD)

 Assess skin
reactions (rash,
fever, edema,
mucosal erosions
or ulcerations,
red or inflamed
eyes). Monitor
patient with mild
to moderate rash
for progression. If
rash becomes
severe or
systemic
symptoms occur,
discontinue
piperacillin/tazob
actam.

 Evaluate renal
and hepatic
function, CBC,
 serum potassium,
and bleeding
times prior to and
routinely during
therapy.

Patient/Family Teaching:

 Continue the
duration of the
drug therapy.
 Report if
itchiness or
rashes occur.
 Use caution
when taking other
drugs such as
drugs containing
aminoglycosides,
methotrexate,
and probenecid.